Search results
Found 18167 matches for
The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.
Paul Harrison
MA, BM. BCh, DM (Oxon), FRCPsych Paul Harrison - Professor of Psychiatry; Associate Head of Department (Research)
Ksenija Yeeles
DPhil, BSc (Hons) Ksenija Yeeles - Associate Research Group Leader, Research Member of Common Room Kellogg College
John Gallacher
PhD AFBPsS CPsychol FFPH John Gallacher - Professor of Cognitive Health; Director, Dementias Platform UK; Director, BrainWaves study of adolescent wellbeing and mental health
Charles Newton
MBChB (UCT), MA (Oxford), MRCP (London), MD (UCT), FRCPCH Charles Newton - Cheryl & Reece Scott Professor of Psychiatry
Michael Sharpe
MA (Oxon), MB BChir, MD (Cantab) Michael Sharpe - Emeritus Professor of Psychological Medicine
Marieke Martens
BSc, MSc, DPhil Marieke Martens - NIHR Oxford Health BRC Senior Postdoctoral researcher
